IL1RL1

Interleukin 1 receptor-like 1
Identifiers
Symbols IL1RL1; DER4; FIT-1; IL33R; MGC32623; ST2; ST2L; ST2V; T1
External IDs OMIM601203 MGI98427 HomoloGene2862 GeneCards: IL1RL1 Gene
RNA expression pattern
More reference expression data
Orthologs
Species Human Mouse
Entrez 9173 17082
Ensembl ENSG00000115602 ENSMUSG00000026069
UniProt Q01638 Q3UM53
RefSeq (mRNA) NM_003856.2 NM_001025602
RefSeq (protein) NP_003847.2 NP_001020773
Location (UCSC) Chr 2:
102.93 – 102.97 Mb
Chr 1:
40.5 – 40.52 Mb
PubMed search [2] [3]

Interleukin 1 receptor-like 1, also known as IL1RL1 and ST2, is a protein that in humans is encoded by the IL1RL1 gene.[1][2][3]

Contents

Molecular biology

The gene is found on the long arm of Chromosome 2 (2q12). It is 40,536 bases long and is located on the Watson (plus) strand. It encodes a protein of 556 amino acids (molecular weight 63,358 Da). Both membrane bound and soluble forms are known. The protein is known to interact with MyD88, IRAK1, IRAK4 and TRAF6. It appears to be essential for the normal function of T helper cells type 2 (Th2 cells).

Clinical significance

ST2 is a novel biomarker of cardiac stress. ST2 signals the presence and severity of adverse cardiac remodeling and tissue [fibrosis]], which occurs in response to myocardial infarction, acute coronary syndrome, or worsening heart failure.[4][5]

Published and peer-reviewed evidence continues to confirm that ST2 is a powerful predictor of mortality at presentation.[6] Studies have shown patients with ST2 levels above a clinical threshold consistently have a much higher risk of mortality while, equally important, patients with ST2 levels below threshold have a very low risk of mortality.[7] There is no level that perfectly separates patients with and without heart failure. However there is shown to be a higher risk of adverse outcomes when ST2 level is above a cutoff value of 35ng/mL.[7]

Mutations in this gene have been linked to atopic dermatitis and asthma.

ST2 cardiac biomarker

ST2 is a member of the interleukin 1 receptor family. The ST2 protein has two isoforms and is directly implicated in the progression of cardiac disease: a soluble form (referred to as soluble ST2 or sST2) and a membrane-bound receptor form (referred to as the ST2 receptor or ST2L). The ligand for ST2 is the cytokine Interleukin-33(IL-33). Binding of IL-33 to the ST2 receptor, in response to cardiac disease or injury, such as an ischemic event, elicits a cardioprotective effect resulting in preserved cardiac function. This cardioprotective IL-33 signal is counter-balanced by the level of soluble ST2, which binds IL-33 and makes it unavailable to the ST2 receptor for cardioprotective signaling. As a result, the heart is subjected to greater stress in the presence of high levels of soluble ST2.

Clinical utility

The ST2 Test

ST2 is measured by immunoassay. The Presage ST2 Assay is the only test that quantitatively measures the level of ST2 in blood. The Presage ST2 Assay is offered exclusively by Critical Diagnostics of San Diego, California. [10] Critical Diagnostics has US Food and Drug Administration FDA 510(k) approval and has CE Mark for the manufacture and sale of The Presage ST2 Assay. [10]

References

  1. ^ "Entrez Gene: IL1RL1 interleukin 1 receptor-like 1". http://www.ncbi.nlm.nih.gov/sites/entrez?Db=gene&Cmd=ShowDetailView&TermToSearch=9173. 
  2. ^ Tominaga S, Yokota T, Yanagisawa K, Tsukamoto T, Takagi T, Tetsuka T (December 1992). "Nucleotide sequence of a complementary DNA for human ST2". Biochim. Biophys. Acta 1171 (2): 215–8. PMID 1482686. 
  3. ^ Dale M, Nicklin MJ (April 1999). "Interleukin-1 receptor cluster: gene organization of IL1R2, IL1R1, IL1RL2 (IL-1Rrp2), IL1RL1 (T1/ST2), and IL18R1 (IL-1Rrp) on human chromosome 2q". Genomics 57 (1): 177–9. doi:10.1006/geno.1999.5767. PMID 10191101. 
  4. ^ Shah RV, Januzzi JL (March 2010). "ST2: a novel remodeling biomarker in acute and chronic heart failure". Curr Heart Fail Rep 7 (1): 9–14. doi:10.1007/s11897-010-0005-9. PMID 20425491. 
  5. ^ a b Rehman SU, Mueller T, Januzzi JL (October 2008). "Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure". J. Am. Coll. Cardiol. 52 (18): 1458–65. doi:10.1016/j.jacc.2008.07.042. PMID 19017513. 
  6. ^ Braunwald E (May 2008). "Biomarkers in heart failure". N. Engl. J. Med. 358 (20): 2148–59. doi:10.1056/NEJMra0800239. PMID 18480207. 
  7. ^ a b Kohli P, Bonaca MP, Kakkar R, Kudinova AY, Scirica BM, Sabatine MS, Murphy SA, Braunwald E, Lee RT, Morrow DA (November 2011). "Role of ST2 in Non-ST-Elevation Acute Coronary Syndrome in the MERLIN-TIMI 36 Trial". Clin. Chem.. doi:10.1373/clinchem.2011.173369. PMID 22096031. 
  8. ^ a b Bayes-Genis A, Pascual-Figal D, Januzzi JL, Maisel A, Casas T, Valdés Chávarri M, Ordóñez-Llanos J (October 2010). "Soluble ST2 monitoring provides additional risk stratification for outpatients with decompensated heart failure". Rev Esp Cardiol 63 (10): 1171–8. PMID 20875357. 
  9. ^ Sabatine MS, Morrow DA, Higgins LJ, MacGillivray C, Guo W, Bode C, Rifai N, Cannon CP, Gerszten RE, Lee RT (April 2008). "Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction". Circulation 117 (15): 1936–44. doi:10.1161/CIRCULATIONAHA.107.728022. PMID 18378613. 
  10. ^ a b [1],

Further reading